Prism Johnson Ltd
PRSMJOHNSNPrism Johnson Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 70th percentile of its own range — the multiple has already done part of the work.
The price is in a downtrend (35 weeks in) while the P/E sits at the 70th percentile of its own 8-year range. Underneath, the last four quarters read deteriorating — profit −113.2% year on year, and 723% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Prism Johnson Ltd trades at ₹106, in a downtrend and 35 weeks into that stage. That is −16.2% against its own 200-day average. It sits at 0% of a 52-week range of ₹106 to ₹168. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (14 weeks and counting).
Today the stock is in a downtrend — week 35 of stage 4, confirmed. At ₹106 it trades −16.2% versus its 200-day average and sits at 0% of its 52-week range (₹106–₹168).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +47% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (14 weeks and counting; last ahead the week of 2026-05-29) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Prism Johnson Ltd trades at 98.1× P/E, at the pricey end of its own range (70th percentile). Its long-run median P/E is 71.5×, measured across 8.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 98.1× is at the pricey end of its own range (70th percentile), against a long-run median of 71.5× measured over 8.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −8.8% against a −29.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −5.1%/yr price move, ~−20.4%/yr came from earnings growth and ~+15.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 131% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Prism Johnson Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.4% | +0.1% | +5.7% | +3.5% |
| Profit | −33.3% | — | −26.5% | +1.8% |
| EPS | −8.8% | — | −15.7% | +37.5% |
| Share price | −29.3% | −5.0% | −5.1% | −0.2% |
4-Factor Sector Score
38.2/100 — rank 23 of 26 in Cement · 69% evidence confidence
Prism Johnson Ltd scores 38.2 out of 100 against the 26 companies it is compared with in Cement, ranking 23. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 12.1 + 5.9 + 8.6 + 11.6 = 38.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Prism Johnson Ltd reported ₹2,110 Cr of revenue in the Mar 26 quarter, +7.7% year on year. Over 10 years it has compounded at 3.5% a year. The last full year, FY26, came in at ₹7,381 Cr. The last four reported quarters add to ₹7,640 Cr.
FY26 revenue came in at ₹7,381 Cr (+8.4% on the year), capping 10 years at 3.5% compound. The latest quarter (Mar 26) printed ₹2,110 Cr, +7.7% year on year.
Pace check: the last four quarters averaged +6.5% growth against the decade's 3.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.3% over the last 4 quarters against +0.4%/yr over the last 8 — accelerating; TTM profit −33.3% vs −57.1%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Prism Johnson Ltd's operating margin is 8.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 4.0% to 11.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 8.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 4.0%–11.0%.
🚨 Why the margin moved: operating margin went −1.8 pp year on year while gross margin went −3.5 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Prism Johnson Ltd posted a net loss of ₹16.0 Cr in the Mar 26 quarter. Full-year FY26 profit was ₹30.0 Cr. The 10-year compound rate is 1.8%. That loss is 0.8% of the quarter's revenue. The same quarter a year earlier earned ₹121 Cr. 6 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹−16.0 Cr, −113.2% year on year. On the full year, FY26 printed ₹30.0 Cr (−33.3%), and the 10-year compound rate is 1.8%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 723% of Prism Johnson Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹503 Cr of operating cash against ₹30.0 Cr of profit. After ₹345 Cr of capital spending, ₹158 Cr was left as free cash.
FY26: operating cash of ₹503 Cr against reported profit of ₹30.0 Cr, leaving free cash of ₹158 Cr after ₹345 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 723% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 723%: the cash cycle stretched 22 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Prism Johnson Ltd's cash conversion cycle runs −7 days in FY26, up from −29 days in FY21. Capital spending ran ₹1,474 Cr over the last 3 years. At FY26 sales of ₹7,381 Cr each day of that cycle holds about ₹20.2 Cr, so roughly ₹−142 Cr sits inside the business at any moment.
FY26: debtors at 39 days, inventory at 94 days — roughly 3.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −7 days, looser than FY21's −29.
The full loop: cash goes out to suppliers and production on day 0; stock waits 94 days to sell; customers pay about 39 days after that; and suppliers themselves are paid at 140 days — netting out to the −7-day cycle.
In money terms: at FY26 sales of ₹7,381 Cr, each day of the cycle holds about ₹20.2 Cr — so the −7-day loop keeps roughly ₹−142 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,474 Cr over the last 3 fiscal years against ₹1,421 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹45.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Prism Johnson Ltd earns a ROCE of 6% in FY26. That is up from a trough of 0% in FY14. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 0.4% net margin on 1.01× asset turns.
FY26 ROCE is 6%, recovered from a FY14 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 0.4% net margin × 1.01× asset turns × 4.80× balance-sheet leverage ≈ 1.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 131% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Prism Johnson Ltd carries ₹1,677 Cr of borrowings against ₹1,528 Cr of equity in FY26, a debt-to-equity of 1.10. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1,930 Cr to ₹1,677 Cr. Capital spending ran ₹1,474 Cr across the last 3 of those years.
FY26: borrowings of ₹1,677 Cr against equity of ₹1,528 Cr — a debt-to-equity of 1.10. Operating profit covers the interest bill 4×. Over 5 years borrowings went from ₹1,930 Cr to ₹1,677 Cr while capital spending ran ₹1,474 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 131% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Prism Johnson Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.5 points over the same window, to 6.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.9 points over 8 quarters to 2.7%; Domestic institutions: +0.5 points over 8 quarters to 6.5%; Promoters: +0.0 points over 8 quarters to 74.9%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Prism Johnson Ltd: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
The safety line in one sentence: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Star Cement LtdSTARCEMENT | 76.0/100Favorable setup90% evidence | ASLEEP | 29.9/35 Revenue 19.4% · PAT 100% · OPM change 2 pp 88% evidence | 22.4/25 ROCE 16.7% · OPM 27% 100% evidence | 11.3/20 P/E 20.4× · PEG 1.11 100% evidence | 12.4/20 RS sector 13.8% · RS bench -13.2% · 1Y -12.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 29.9 + 22.4 + 11.3 + 12.4 = 76 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NCL Industries LtdNCLIND | 69.7/100Favorable setup83% evidence | FADING | 25.3/35 Revenue 1.8% · PAT 100% · OPM change 7 pp 83% evidence | 18.0/25 ROCE 14.5% · OPM 13% 95% evidence | 15.0/20 P/E 6.3× · PEG — 50% evidence | 11.4/20 RS sector 2.1% · RS bench -6.3% · 1Y -18.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 18 + 15 + 11.4 = 69.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3UltraTech Cement LtdULTRACEMCO | 63.1/100Mixed-positive evidence76% evidence | TURNING | 21.9/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.2/20 P/E 40.7× · PEG — 50% evidence | 14.9/20 RS sector 17% · RS bench -1.4% · 1Y -2.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 17.1 + 9.2 + 14.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Mangalam Cement LtdMANGLMCEM | 62.9/100Mixed-positive evidence96% evidence | FADING | 21.6/35 Revenue 4.6% · PAT 100% · OPM change 0 pp 88% evidence | 11.7/25 ROCE 11% · OPM 11% 100% evidence | 16.0/20 P/E 17.5× · PEG 0.6 100% evidence | 13.6/20 RS sector 24.1% · RS bench 14.9% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.7 + 16 + 13.6 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rain Industries LtdRAIN | 62.5/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.9/35 Revenue 14.4% · PAT 100% · OPM change 5 pp 62% evidence | 9.4/25 ROCE 8.3% · OPM 15% 76% evidence | 10.2/20 P/E 24.9× · PEG — 15% evidence | 20.0/20 RS sector 61.8% · RS bench 49.7% · 1Y 43.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 9.4 + 10.2 + 20 = 62.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Orient Cement LtdORIENTCEM | 58.2/100Mixed-positive evidence93% evidence | ASLEEP | 17.6/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 13.2× · PEG 0.25 65% evidence | 7.6/20 RS sector -12% · RS bench -20.1% · 1Y -45.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.9 + 16.1 + 7.6 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Dalmia Bharat LtdDALBHARAT | 53.4/100Mixed-positive evidence94% evidence | ASLEEP | 13.0/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 12.8/25 ROCE 7.6% · OPM 21% 100% evidence | 15.3/20 P/E 30.7× · PEG 0.72 100% evidence | 12.3/20 RS sector 12.6% · RS bench -11.9% · 1Y -19.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 12.8 + 15.3 + 12.3 = 53.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Shree Cement LtdSHREECEM | 51.8/100Mixed-positive evidence97% evidence | BREAKING OUT | 15.0/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 95% evidence | 13.0/25 ROCE 10.3% · OPM 20% 95% evidence | 9.2/20 P/E 57.7× · PEG 0.96 100% evidence | 14.6/20 RS sector 5.1% · RS bench -3.7% · 1Y -15.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 13 + 9.2 + 14.6 = 51.8 · Decision use: Price leads the evidence: RS versus the benchmark is -3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9JSW Cement LtdJSWCEMENT | 50.8/100Thin evidence · provisional51% evidence | TURNING | 18.6/35 Revenue 12% · PAT -80% · OPM change 5 pp 83% evidence | 12.1/25 ROCE 11.1% · OPM 19% 76% evidence | 10.1/20 P/E 27.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -8.9%5 of 10 weeks ahead 0% evidence |
| Exact sum: 18.6 + 12.1 + 10.1 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10K C P LtdKCP | 49.4/100Mixed-negative evidence77% evidence | ASLEEP | 13.5/35 Revenue 1.9% · PAT 8.7% · OPM change 1 pp 83% evidence | 16.1/25 ROCE 12.2% · OPM 17% 95% evidence | 13.9/20 P/E 10.3× · PEG — 50% evidence | 5.9/20 RS sector -14% · RS bench -9.4% · 1Y -23.5%3 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 16.1 + 13.9 + 5.9 = 49.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11HeidelbergCement India LtdHEIDELBERG | 48.6/100Mixed-negative evidence100% evidence | ASLEEP | 14.5/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.7/25 ROCE 14.7% · OPM 11% 100% evidence | 13.7/20 P/E 28.5× · PEG 0.82 100% evidence | 5.7/20 RS sector -5.1% · RS bench -13.3% · 1Y -28.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.7 + 13.7 + 5.7 = 48.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12J K Cements LtdJKCEMENT | 48.1/100Mixed-negative evidence94% evidence | TURNING | 11.2/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.4/25 ROCE 15.1% · OPM 16% 100% evidence | 8.1/20 P/E 43.1× · PEG 1.46 100% evidence | 12.4/20 RS sector 10.4% · RS bench -7.1% · 1Y -16%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 16.4 + 8.1 + 12.4 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13The Ramco Cements LtdRAMCOCEM | 47.3/100Mixed-negative evidence90% evidence | ASLEEP | 20.6/35 Revenue 6% · PAT 100% · OPM change 1 pp 88% evidence | 13.2/25 ROCE 6.1% · OPM 14% 100% evidence | 1.2/20 P/E 732× · PEG 4.14 100% evidence | 12.3/20 RS sector 11.1% · RS bench -10.1% · 1Y -19.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 13.2 + 1.2 + 12.3 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14JK Lakshmi Cement LtdJKLAKSHMI | 47.3/100Mixed-negative evidence65% evidence | ASLEEP | 17.4/35 Revenue 9.2% · PAT 49.6% · OPM change -5 pp 83% evidence | 13.9/25 ROCE 12% · OPM 14% 76% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 5.4/20 RS sector -8.2% · RS bench -23.6% · 1Y -40.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.4 + 13.9 + 10.6 + 5.4 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Nuvoco Vistas Corporation LtdNUVOCO | 47.1/100Mixed-negative evidence87% evidence | TURNING | 21.0/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 9.6/25 ROCE 7.1% · OPM 18% 100% evidence | 4.8/20 P/E 29.7× · PEG 8.14 65% evidence | 11.7/20 RS sector 3.6% · RS bench -5% · 1Y -16.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 9.6 + 4.8 + 11.7 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16India Cements LtdINDIACEM | 45.4/100Mixed-negative evidence75% evidence | ASLEEP | 21.3/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.8/25 ROCE 1.2% · OPM 15% 100% evidence | 5.4/20 P/E 91.4× · PEG — 50% evidence | 14.9/20 RS sector 20% · RS bench -2% · 1Y 10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.3 + 3.8 + 5.4 + 14.9 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Deccan Cements LtdDECCANCE | 43.7/100Mixed-negative evidence70% evidence | ASLEEP | 22.6/35 Revenue 20.6% · PAT 100% · OPM change -3 pp 83% evidence | 7.9/25 ROCE 3.3% · OPM 8.1% 95% evidence | 9.1/20 P/E 43.4× · PEG — 15% evidence | 4.1/20 RS sector -12.9% · RS bench -29.1% · 1Y -47.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.6 + 7.9 + 9.1 + 4.1 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18ACC LtdACC | 42.5/100Mixed-negative evidence94% evidence | ASLEEP | 9.1/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.9/25 ROCE 11.2% · OPM 8% 100% evidence | 16.7/20 P/E 13.4× · PEG 0.92 100% evidence | 6.8/20 RS sector -6.7% · RS bench -16.8% · 1Y -26.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 9.9 + 16.7 + 6.8 = 42.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Birla Corporation LtdBIRLACORPN | 41.0/100Mixed-negative evidence94% evidence | ASLEEP | 17.4/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 10.4/25 ROCE 9.8% · OPM 13% 100% evidence | 8.8/20 P/E 12.3× · PEG 3.92 100% evidence | 4.4/20 RS sector -14% · RS bench -17.4% · 1Y -37.4%3 of 9 weeks ahead 70% evidence |
| Exact sum: 17.4 + 10.4 + 8.8 + 4.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Sagar Cements LtdSAGCEM | 41.0/100Mixed-negative evidence66% evidence | ASLEEP | 19.5/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.1/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -8.1% · RS bench -16.3% · 1Y -28.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 5.1 + 10 + 6.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 38.9/100Mixed-negative evidence82% evidence | ASLEEP | 9.4/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.6/20 P/E 22.8× · PEG — 50% evidence | 5.9/20 RS sector -7.2% · RS bench -15.1% · 1Y -29.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 11 + 12.6 + 5.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Saurashtra Cement LtdSAURASHCEM | 38.8/100Mixed-negative evidence76% evidence | ASLEEP | 19.7/35 Revenue 8.4% · PAT 87.5% · OPM change -5 pp 83% evidence | 4.8/25 ROCE 2.5% · OPM 6% 95% evidence | 9.5/20 P/E 30.9× · PEG — 15% evidence | 4.8/20 RS sector -16.6% · RS bench -24.6% · 1Y -41.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 4.8 + 9.5 + 4.8 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Prism Johnson Ltdthis pagePRSMJOHNSN | 38.2/100Mixed-negative evidence69% evidence | ASLEEP | 12.1/35 Revenue 6.3% · PAT -33.3% · OPM change -2 pp 83% evidence | 5.9/25 ROCE 5.9% · OPM 8% 76% evidence | 8.6/20 P/E — · PEG — 35% evidence | 11.6/20 RS sector 14.3% · RS bench -20.9% · 1Y -32.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 5.9 + 8.6 + 11.6 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BIGBLOC Construction LtdBIGBLOC | 36.7/100Thin evidence · provisional59% evidence | ASLEEP | 15.4/35 Revenue 26.2% · PAT -80% · OPM change -1.6 pp 62% evidence | 5.8/25 ROCE 1.8% · OPM 7.3% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -9.7% · RS bench -17.9% · 1Y -24.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 5.8 + 10 + 5.5 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Shree Digvijay Cement Co. LtdSHREDIGCEM | 31.2/100Adverse evidence81% evidence | ASLEEP | 10.8/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.2/25 ROCE 6.4% · OPM 8.7% 95% evidence | 6.1/20 P/E 59.4× · PEG — 50% evidence | 6.1/20 RS sector -12.4% · RS bench -10.9% · 1Y -15.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 10.8 + 8.2 + 6.1 + 6.1 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shiva Cement LtdSHIVACEM | 36.5/100Thin evidence · provisional42% evidence | 18.1/35 Revenue 19.7% · PAT -47.1% · OPM change 15 pp 40% evidence | 5.4/25 ROCE -3% · OPM 1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -27.5% · RS bench -36.4% · 1Y -54.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 18.1 + 5.4 + 10 + 3 = 36.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Prism Johnson Ltd's share price today?
Prism Johnson Ltd trades at ₹106, −29.3% over the past year. The company is valued at ₹5,359 Cr. The stock sits at 0% of its 52-week range of ₹106–₹168, −16.2% versus its 200-day average. On the tape, the price is in a downtrend, 35 weeks in. — as of 31 July 2026.
What were Prism Johnson Ltd's latest quarterly results?
Prism Johnson Ltd reported revenue of ₹2,110 Cr and a net loss of ₹16.0 Cr for the Mar 26 quarter. Revenue rose 7.7% and profit fell 113.2% year on year. The operating margin was 8.0%, 2.0 pp lower than a year earlier. — as of 31 July 2026.
What is Prism Johnson Ltd's revenue?
Prism Johnson Ltd reported revenue of ₹2,110 Cr in the Mar 26 quarter, +7.7% year on year. For the full FY26 fiscal year, revenue was ₹7,381 Cr (+8.4%). Over the last 10 years revenue compounded at 3.5% a year. — as of 31 July 2026.
What is Prism Johnson Ltd's profit?
Prism Johnson Ltd earned ₹−16.0 Cr of net profit in the Mar 26 quarter, −113.2% year on year. Full-year FY26 profit was ₹30.0 Cr. The operating margin ran 8.0% in the latest quarter. — as of 31 July 2026.
What is Prism Johnson Ltd's market cap?
Prism Johnson Ltd's market capitalisation is ₹5,359 Cr at a share price of ₹106. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Prism Johnson Ltd's P/E ratio?
Prism Johnson Ltd trades at a P/E of 98.1×, at the 70th percentile of its own 8-year range, against a long-run median of 71.5×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Prism Johnson Ltd pay a dividend?
Not in its latest year — Prism Johnson Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 2 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Prism Johnson Ltd overvalued?
On its own history, Prism Johnson Ltd looks expensive against its own history: its P/E of 98.1× sits at the 70th percentile of its 8-year range (long-run median 71.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Prism Johnson Ltd growing?
Not right now — Prism Johnson Ltd's latest numbers are shrinking: latest-quarter revenue +7.7% year on year, profit −113.2%, and the margin −2.0 pp at 8.0%. The 10-year compound rates are 3.5% (revenue) and 1.8% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Prism Johnson Ltd performing?
Prism Johnson Ltd is in a downtrend, 35 weeks in. Its latest quarter's revenue rose 7.7% and profit fell 113.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Prism Johnson Ltd in an uptrend?
No — the price is in a downtrend (week 35 of stage 4), trading −16.2% versus its 200-day average and at 0% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Prism Johnson Ltd beating the market?
Not lately — on a trailing-13-week view Prism Johnson Ltd is currently behind the NIFTY 500 (14 weeks and counting; last ahead the week of 2026-05-29), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +47% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Prism Johnson Ltd's share price go up?
This page publishes no price forecast for Prism Johnson Ltd. What it measures instead: the share price is ₹106, the price is in a downtrend 35 weeks in. Its P/E of 98.1× sits at the 70th percentile of its own 8-year range. — as of 31 July 2026.
Who owns Prism Johnson Ltd?
Promoters hold 74.9% of Prism Johnson Ltd, foreign institutions 2.7%, domestic institutions 6.5% and the public 15.9% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Prism Johnson Ltd have too much debt?
It carries real leverage — Prism Johnson Ltd's debt-to-equity is 1.10, and operating profit covers the interest bill 4×. FY26 borrowings were ₹1,677 Cr against equity of ₹1,528 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Prism Johnson Ltd's capex?
Prism Johnson Ltd spent ₹1,474 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹345 Cr, with ₹45.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Prism Johnson Ltd's cash flow?
Prism Johnson Ltd generated ₹503 Cr of operating cash flow in FY26 and ₹158 Cr of free cash flow after ₹345 Cr of capital spending. Reported profit that year was ₹30.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Prism Johnson Ltd's profit real cash?
Yes — over the last 3 fiscal years, 723% of Prism Johnson Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹503 Cr against reported profit of ₹30.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Prism Johnson Ltd in its business cycle?
Prism Johnson Ltd's FY26 operating margin was 9.0%, against a 13-year band of 4.0%–11.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 8.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Prism Johnson Ltd story?
Biggest watch item: the P/E sits at the 70th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Prism Johnson Ltd a stock worth studying right now?
This is not investment advice. The machine read: Prism Johnson Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.